Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 61-72 of 79 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 61-72 of 79 studies
-
Restore CFTR ProteinCompleted with Results
Ivacaftor in People with CF age 2 to 5 years with a CFTR Gating Mutation , protocol number Vertex VX-770-108This was an open-label study designed to look at the safety and effectiveness of ivacaftor (Kalydeco®) in children with CF who had at least one copy of a CFTR gating mutation.
-
Age:
2 Years to 5 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
11
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ivacaftor in People with CF who have a Non G551D Gating Mutation (KONNECTION) , protocol number Vertex VX-770-111The purpose of this trial was to look at the safety and effectiveness of ivacaftor (Kalydeco) in people with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 105%
-
Number of Visits:
11
-
Length of Participation:
40 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ivacaftor in People with CF who have the R117H-CFTR mutation (KONDUCT) , protocol number Vertex VX-770-110This study looked at the safety and effectiveness of ivacaftor (Kalydeco) in people with CF who have the R117H-CFTR mutation.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 105%
-
Number of Visits:
8
-
Length of Participation:
28 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-101This study looked at the safety and effectiveness of multiple dose levels of VX-661 alone and in combination with ivacaftor (Kalydeco®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
84 days
-
-
Restore CFTR ProteinCompleted with Results
VX-770 Expanded Access Program , protocol number Vertex VX11-770-901This open-label expanded access program (EAP) study was designed to provide ivacaftor to patients in critical medical need prior to commercial product availability.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
Less than 40%
-
Number of Visits:
1
-
Length of Participation:
9 months
-
-
Restore CFTR ProteinCompleted with Results
Vertex 770 - a phase 2 trial evaluating the effect of VX- 770 on Lung Clearance Index , protocol number Vertex VX10-770-106This trial studied the effect of VX-770 (ivacaftor) on lung clearance index in people with CF ages 6 years and older with the G551D mutation and an FEV1 >90%.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
90% or greater
-
Number of Visits:
8
-
Length of Participation:
19 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX-770 in People with CF and G551D Mutation - Open Label Safety Study (PERSIST) , protocol number Vertex VX-770-105This study looked at the long-term safety of ivacaftor in people with CF and the G551D mutation. Subjects received ivacaftor for 96 weeks during this study.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
10
-
Length of Participation:
2 years
-
-
Restore CFTR ProteinCompleted with Results
VX-770 Phase 2 study in People with CF and Genotype G551D , protocol number Vertex VX06-770-101This Phase 2 clinical study looked at the safety and tolerability of ivacaftor (VX-770) in people with CF and at least one allele with the G551D CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
56 days
-
-
Restore CFTR ProteinCompleted with Results
Vertex-770 in People with CF with Homozygous Delta F508 Mutation (DISCOVER) , protocol number Vertex 770-104This study looked at the safety and effectiveness of VX-770 (ivacaftor), in people with Cystic Fibrosis (CF) age 12 years and older, with homozygous Delta F508 mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
22 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex-770 and the G551D mutation (STRIVE) , protocol number Vertex VX08-770-102This phase 3 study looked at the safety and effectiveness of ivacaftor (VX-770) in adolescents and adults with CF and the G551D mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
54 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex 770 in Children with CF and the G551 Mutation (ENVISION) , protocol number Vertex VX08-770-103This phase 3 study looked at the safety and effectiveness of ivacaftor (VX-770) in people with CF aged 6 to 11 years with the G551D mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
54 weeks
-
-
Mucociliary ClearanceCompleted with Results
Phase 1b study of inhaled AZD5634 in adults with CF , protocol number AstraZeneca D6600C00002This study evaluated the safety and tolerability of the inhaled drug AZD5634 in people with CF. It also evaluated the effect of AZD5634 on improving the ability to clear mucus from the lungs (lung mucociliary clearance - MCC).
-
Age:
18 Years to 60 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
4
-
Length of Participation:
4 months
-
Showing 61-72 of 79 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More